Function-enhanced iPSC-derived NK cell and application thereof

By inserting an IL-15 secretion expression fragment into iPSCs and blocking PD-1 expression, the problems of standardization and activity maintenance of NK cell sources were solved, thereby enhancing the killing function and therapeutic effect of NK cells.

CN118995599APending Publication Date: 2024-11-22HANGZHOU JIYUAN GENE TECH CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411092833.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing NK cell sources suffer from problems such as difficulty in standardization and homogenization of production, immature phenotype, low CD16 expression, short duration of cell activity in vivo and in vitro, and susceptibility to cancer cells evading immune surveillance, which affect the efficacy of allogeneic natural killer cell therapy.

Method used

The human interleukin-15 (IL-15) secretion expression fragment was inserted into iPSCs using the CRISPR/Cas9 gene editing system to block PD-1 gene expression and overexpress IL-15, thereby preparing functionally enhanced iPSC-derived NK cells that ensured the cells could continuously secrete IL-15 and inhibit PD-1 protein expression.

Benefits of technology

This achieves efficient expansion and sustained activity maintenance of NK cells, enhances tumor-killing ability, prevents immune escape, and ensures the homogeneity and sustainable therapeutic effect of NK cell products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995599A_ABST
    Figure CN118995599A_ABST
Patent Text Reader

Abstract

The invention provides a function-enhanced iPSC (induced pluripotent stem cell)-derived NK (natural killer) cell and application thereof, and also provides a recombinant induced pluripotent stem cell which is prepared by a method comprising the following steps: taking an initial induced pluripotent stem cell as a starting cell, blocking / inhibiting the expression of PD-1 and over-expressing human interleukin 15. The invention also provides the function-enhanced NK cell derived from the iPSC and a construction method of the pluripotent stem cell capable of producing the function-enhanced NK cell. The function-enhanced NK cell derived from the pluripotent stem cells can automatically secrete IL-15, so that the function-enhanced NK cell has lasting activity keeping ability and tumor killing ability in vitro and in vivo, and meanwhile, the activity of the cell is enhanced due to the fact that the expression of PD-1 protein is blocked. The function-enhanced NK cell overcomes tumor cell tolerance and immune escape caused by expression of an immune checkpoint PD-1, and further function enhancement is shown.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biopharmaceuticals, and specifically relates to a functionally enhanced iPSC-derived NK cell and an application thereof. Background Art

[0002] Allogeneic natural killer (NK) cell therapy has made rapid progress in the treatment of cancer, especially for the treatment of hematological malignancies. Unlike T cells, NK cells have a reduced risk of GVHD, so it is possible to produce "off-the-shelf" allogeneic cell therapy products that can be prepared in advance and provided to multiple patients at any time as needed. Currently, clinical-grade NK cells can be mass-produced from a variety of sources, including NK92 cell lines, human peripheral blood cells (PBMCs), umbilical cord blood (UCB), and induced pluripotent stem cells (iPSCs).

[0003] Currently, many NK cell clinical trials use the NK92 cell line because it has unlimited proliferation capacity in vitro and may reduce sensitivity to repeated freeze / thaw cycles. However, as a tumor cell line, NK92 cells have inherent disadvantages, including potential tumorigenic risk, lack of CD16 and NKp44 expression, and loss of in vivo expansion potential due to lethal irradiation required before infusion, making it unlikely to be an ideal NK cell source; human PBMC is an important source of primary NK cells and has been used in many clinical trials. However, NK cells account for only 5-15% of peripheral blood cells, making it difficult to obtain sufficient numbers of NK cells for the treatment of tumor patients. At the same time, due to its limited expansion capacity, it is difficult to obtain a large number of standardized NK cell products from the same source; umbilical cord blood UCB NK cells also have a less mature phenotype and lower cytotoxicity to tumor cells, reduced expression of certain adhesion molecules, CD16, KIRs, perforin and granzyme B, higher expression of inhibitory molecules such as NKG2A, and limited sources from the same donor and difficult to standardize.

[0004] Compared with the above-derived NK cells, iPSC (induced pluripotent stem cells) can be more efficiently engineered to stably obtain sufficient and homogenized NK cells. iPSC can be cultured in a medium containing stem cell factor (SCF), vascular endothelial growth factor (VEGF), and bone morphogenetic protein 4 (BMP4) to differentiate into hematopoietic progenitor cells; then hematopoietic progenitor cells are stimulated with IL3, IL-15, IL-7, SCF, and FLT3L in the culture medium to differentiate into NK cells; finally, irradiated membrane-expressing interleukin 21 K562 trophoblast cells are used for activation and expansion culture for 14-21 days to obtain highly pure induced NK cells. In this process, only one iPSC cell is sufficient to differentiate into a large number of highly homogeneous NK cell products for clinical use. However, iPSCs-derived NK cells, similar to UCB NK cells, are often characterized by an immature phenotype, with lower KIR and CD16 expression and higher NKG2A expression compared to PB-NK cells.

[0005] However, considering that iPSC-derived NK cells are more likely to allow conventional targeted introduction of genetic modifications, and differentiation and expansion to obtain NK cells from the same cloned starting cell line, so that NK cell products have better homogeneity and are easier to obtain in a standardized manner, more research is still focused on using genetic modification to improve the tumor targeting of iNK cells and enhance their expansion, killing activity and persistence. Therefore, it is of great significance to solve the problems of the currently known iNK cells, such as the more immature phenotype, low CD16 expression, short in vivo and in vitro cell activity maintenance time, etc., which cause insufficient tumor killing activity, and the susceptibility of NK cells to escape NK cell immune surveillance by cancer cells through the expression of several checkpoint proteins that inhibit or block the activation of immune cells, for the research and application of allogeneic natural killer (NK) cell therapy. Summary of the invention

[0006] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a functionally enhanced iPSC-derived NK cell and its application. The functionally enhanced iPSC-derived NK cell of the present invention is a universal iNK cell, which not only solves the problem that NK cells from sources such as PBMC are difficult to standardize and homogenize, but also performs precise genetic engineering and editing on iPSC (induced pluripotent stem cells), providing feasibility for obtaining re-modified NK cells, which is expected to further improve the efficacy and solve the anti-tumor defects of natural NK cells.

[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a recombinant induced pluripotent stem cell, wherein the recombinant induced pluripotent stem cell is prepared by a method comprising the following steps: using initial induced pluripotent stem cells as starting cells, blocking / inhibiting the expression of PD-1 and overexpressing human interleukin 15;

[0009] The human interleukin 15 includes any one of the following:

[0010] (1) Human interleukin 15;

[0011] (2) membrane-bound human interleukin-15;

[0012] (3) A protein expressed by fusion of part or all of the structural domains of human interleukin 15 and interleukin 15 receptor subunit α.

[0013] In the present invention, a human interleukin 15 (IL-15) secretory expression fragment is inserted into the recombinant induced pluripotent stem cell, and the insertion site of the human interleukin 15 (IL-15) secretory expression fragment is located in the PD-1 exon sequence of the recombinant induced pluripotent stem cell, which can simultaneously block the expression of the PD-1 gene; the edited recombinant induced pluripotent stem cell is named JY-815iPS cell in the present invention; the induced pluripotent stem cell before editing is named JY-800iPS cell.

[0014] Preferably, the method of blocking / inhibiting the expression of PD-1 and overexpressing human interleukin 15 comprises:

[0015] The CRISPR / Cas9 gene editing system was used to insert a homologous recombination fragment containing a nucleotide fragment encoding human interleukin 15 into the PD-1 gene, thereby blocking / inhibiting the expression of PD-1 while overexpressing human interleukin 15.

[0016] Preferably, the CRISPR / Cas9 gene editing system comprises sgRNA, Cas9 plasmid and donor plasmid.

[0017] Preferably, the donor plasmid contains a homologous recombination fragment, and the homologous recombination fragment contains a nucleotide fragment encoding human interleukin-15.

[0018] Preferably, the homologous recombination fragment comprises an upstream homology arm, an insertion fragment and a downstream homology arm.

[0019] In the present invention, the inserted fragment can be inserted between the upstream homology arm and the downstream homology arm in a forward or reverse direction.

[0020] Preferably, the inserted fragment comprises a promoter element, a nucleotide sequence encoding human interleukin 15 and a poly A element.

[0021] Preferably, the homologous recombination fragment comprises an upstream homology arm, a 5'ITR, a poly A element, a nucleotide sequence encoding human interleukin 15, a PGK promoter element, a 3'ITR and a downstream homology arm.

[0022] Preferably, the poly A element is selected from SV40 (including simian virus 40 or monkey virus 40); the poly A element further comprises a terminator, and the terminator is selected from any one of bGH, hGH or rbGlob.

[0023] Preferably, the promoter is selected from any one of PGK, CAG, CMV, EF1a or UBC.

[0024] Preferably, the amino acid sequence of human interleukin 15 includes that shown in SEQ ID NO.16; the nucleotide sequence encoding human interleukin 15 includes that shown in SEQ ID NO.13.

[0025] Preferably, the amino acid sequence of the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.17; the nucleotide sequence encoding the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.18.

[0026] Preferably, the protein expressed by fusion of part or all of the structural domains of human interleukin 15 and interleukin 15 receptor subunit α is a protein expressed by fusion of the extracellular domain and transmembrane domain of human interleukin 15 and interleukin 15 receptor subunit α, and its nucleotide sequence includes that shown in SEQ ID NO.19; the nucleotide sequence encoding the fusion expressed protein includes that shown in SEQ ID NO.20;

[0027] Preferably, the nucleotide sequence of the inserted fragment is shown as SEQ ID NO.9.

[0028] Preferably, the site targeted by the sgRNA is exon 1 or 2 of the PD-1 gene of induced pluripotent stem cells.

[0029] Preferably, the DNA sequence corresponding to the sgRNA includes any one of SEQ ID NO.1-8.

[0030] In a specific embodiment, the site targeted by the sgRNA is located within the exon of the PD-1 gene, successfully destroying the transcription structure of PD-1 and inhibiting the expression of PD-1 protein, thereby enabling the edited immune cells to overcome the problems of tumor cell tolerance and immune escape caused by the expression of the immune checkpoint PD-1, and enabling the immune cells to acquire more sustained tumor recognition and killing capabilities.

[0031] In a second aspect, the present invention provides a recombinant plasmid for expressing human interleukin-15, wherein the recombinant plasmid contains a homologous recombination fragment, and the homologous recombination fragment contains a nucleotide fragment encoding human interleukin-15.

[0032] Preferably, the human interleukin 15 includes any one of the following:

[0033] (1) Human interleukin 15;

[0034] (2) membrane-bound human interleukin-15;

[0035] (3) A protein expressed by fusion of part or all of the structural domains of human interleukin 15 and interleukin 15 receptor subunit α.

[0036] Preferably, the homologous recombination fragment comprises an upstream homology arm, an insertion fragment and a downstream homology arm.

[0037] Preferably, the inserted fragment comprises a promoter element, a nucleotide sequence encoding human interleukin 15 and a poly A element.

[0038] Preferably, the poly A element is selected from SV40, and a transcription terminator is further included after the poly A element, and the transcription terminator is selected from any one of bGH, hGH or rbGlob.

[0039] Preferably, the promoter is selected from any one of PGK, CAG, CMV, EF1a or UBC.

[0040] Preferably, the amino acid sequence of human interleukin 15 includes that shown in SEQ ID NO.16; the nucleotide sequence encoding human interleukin 15 includes that shown in SEQ ID NO.13.

[0041] Preferably, the amino acid sequence of the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.17; the nucleotide sequence encoding the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.18.

[0042] Preferably, the protein expressed by fusion of part or all of the structural domains of human interleukin 15 and interleukin 15 receptor subunit α is a protein expressed by fusion of the extracellular domain and transmembrane domain of human interleukin 15 and interleukin 15 receptor subunit α, and its amino acid sequence includes that shown in SEQ ID NO.19; the nucleotide sequence encoding the fusion expressed protein includes that shown in SEQ ID NO.20.

[0043] Preferably, the nucleotide sequence of the inserted fragment is shown as SEQ ID NO.9.

[0044] Preferably, the backbone vector of the recombinant plasmid is pUC19.

[0045] In a third aspect, the present invention provides an application of the recombinant plasmid expressing human interleukin 15 according to the second aspect, the application comprising:

[0046] (a) as a donor plasmid for in vitro genetic modification of any stem cell including iPSC, ESC, or any immune cell including NK cell, T cell, γδT cell, NKT or macrophage;

[0047] (b) as a donor plasmid for in vivo gene editing;

[0048] (c) As a donor plasmid for gene therapy.

[0049] In a fourth aspect, the present invention provides the use of the recombinant induced pluripotent stem cells described in the first aspect in the preparation of any one of function-enhanced iPSC-derived NK cells, T cells, γδT cells, NKT cells, macrophages or MSC cells.

[0050] In the present invention, the recombinant induced pluripotent stem cell JY-815 can be treated by different differentiation, induction and amplification methods to obtain a series of functionally enhanced iPSC-derived immune cells, including NK cells, T cells, γδT cells, NKT cells, macrophages or MSC cells.

[0051] In a fifth aspect, the present invention provides a function-enhanced iPSC-derived NK cell, wherein the NK cell is obtained by subjecting the recombinant induced pluripotent stem cell described in the first aspect to hematopoietic differentiation culture.

[0052] In the present invention, the functionally enhanced iPSC-derived NK cells are universal iNK cells, and a human interleukin 15 (IL-15) expression fragment is inserted into the genome of the functionally enhanced iPSC-derived NK cells; the insertion site of the human interleukin 15 (IL-15) expression fragment is located in the PD-1 exon sequence of the NK cells, and can simultaneously play a role in blocking the expression of the PD-1 gene; the specific insertion in the functionally enhanced iPSC-derived NK cells is completed in an unedited iPS cell line, and then the edited iPS cell line is induced to differentiate and produce.

[0053] In the present invention, JY-800iPS cells are used as a basis, and JY-815iPS cells are obtained after specific editing by CRISPR / Cas9 technology. The JY-815iPS cells are differentiated, induced, and amplified to obtain functionally enhanced iPSC-derived NK cells, namely JY-815iNK cells.

[0054] In the present invention, the gene modification of JY-815iNK cells is carried out on an undifferentiated iPS cell line, and gene insertion and knockout occur in the undifferentiated iPS cell line. The established PSC monoclonal line is permanent and stable, and the cell line can be used to produce homogeneous iNK cells in unlimited quantities without the need to transfect NK cells with viral vectors, thereby avoiding massive cell death caused by viral infection and uncontrollable changes in gene insertion and expression.

[0055] The present invention selects to insert the gene expression fragment into the gene site corresponding to the PD-1 exon in the iPSC cell line, thereby blocking the transcriptional expression of the PD-1 gene in the obtained JY-815iNK cells, thereby enabling the JY-815iNK cells to overcome the tumor cell tolerance and immune escape caused by the expression of the immune checkpoint PD-1, and enabling the JY-815iNK cells to obtain a more lasting tumor killing ability.

[0056] Furthermore, the human interleukin 15 (IL-15) secretory expression fragment was inserted into the exon sequence of human programmed cell death receptor 1 (PD-1), and the transcriptional expression of PD-1 protein in JY-815iNK cells was blocked by specific insertion and accurate silencing, while ensuring that the obtained JY-815iNK cells can secrete IL-15 normally. While reducing its dependence on the addition of exogenous factors, it can enhance its own expansion ability and the persistence of in vivo and in vitro activity maintenance.

[0057] In the present invention, the insertion of IL-15 expression gene fragments and the silencing of PD-1 gene improve the expansion ability and activity maintenance ability of JY-815 cell-related products as a whole, while avoiding the immune escape of tumor cells caused by the expression of PD-1, thereby improving the killing function of JY-815iNK cells as a whole.

[0058] Preferably, the step of hematopoietic differentiation culture comprises:

[0059] (1) Hematopoietic differentiation: placing the recombinant induced pluripotent stem cells described in the first aspect in a hematopoietic differentiation induction medium for incubation;

[0060] (2) NK differentiation: placing the recombinant induced pluripotent stem cells after hematopoietic differentiation in a NK differentiation induction medium for incubation; obtaining the functionally enhanced iPSC-derived NK cells.

[0061] Preferably, the hematopoietic differentiation induction medium comprises, by concentration:

[0062] 20-60ng / mL fibroblast growth factor (bFGF), 20-60ng / mL bone morphogenetic protein 4 (BMP-4), 5-100ng / mL stem cell factor (SCF), and 10-30ng / mL vascular endothelial growth factor (VEGF).

[0063] Among them, 20-60ng / mL can be, for example, 20ng / mL, 25ng / mL, 30ng / mL, 35ng / mL, 40ng / mL, 45ng / mL, 50ng / mL, 55ng / mL or 60ng / mL, etc.; 5-100ng / mL can be, for example, 5ng / mL, 10ng / mL, 20ng / mL, 30ng / mL, 40ng / mL, 50ng / mL, 60ng / mL, 70ng / mL, 80ng / mL, 90ng / mL or 100ng / mL, etc.; 10-30ng / mL can be, for example, 10ng / mL, 15ng / mL, 20ng / mL, 25ng / mL or 30ng / mL, etc.;

[0064] Preferably, the NK differentiation induction medium comprises, by concentration:

[0065] 5-25% FBS, 5-50 ng / mL interleukin-15 (IL-15), 5-50 ng / mL interleukin-7 (IL-7), 5-100 ng / mL stem cell factor (SCF), and 5-100 ng / mL fms-like tyrosine kinase-3 ligand (Flt3L).

[0066] Among them, 5-25% can be, for example, 5%, 10%, 15%, 20% or 25%, etc.; 5-50ng / mL can be, for example, 5ng / mL, 10ng / mL, 15ng / mL, 20ng / mL, 25ng / mL, 30ng / mL, 35ng / mL, 40ng / mL, 45ng / mL or 50ng / mL, etc.; 5-100ng / mL can be, for example, 5ng / mL, 10ng / mL, 20ng / mL, 30ng / mL, 40ng / mL, 50ng / mL, 60ng / mL, 70ng / mL, 80ng / mL, 90ng / mL or 100ng / mL, etc.

[0067] Preferably, the hematopoietic differentiation incubation time is 6-14 days, for example, 6, 8, 10, 12 or 14 days.

[0068] Preferably, during the NK differentiation process, fresh culture medium is replaced every 3-4 days (eg, 3 or 4, etc.).

[0069] Preferably, the NK differentiation incubation time is 14-21 days, for example, it can be 14, 15, 16, 17, 18, 19, 20 or 21 days.

[0070] In a sixth aspect, the present invention provides a pharmaceutical composition comprising the function-enhanced iPSC-derived NK cells described in the fifth aspect.

[0071] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0072] In a seventh aspect, the present invention provides the use of the recombinant induced pluripotent stem cells described in the first aspect, the functionally enhanced iPSC-derived NK cells described in the fifth aspect and / or the pharmaceutical composition described in the sixth aspect in the preparation of tumor therapeutic drugs.

[0073] The numerical range described in the present invention not only includes the point values ​​listed above, but also includes any point values ​​between the above numerical ranges that are not listed. Due to space limitations and for the sake of simplicity, the present invention no longer exhaustively lists the specific point values ​​included in the range.

[0074] Compared with the prior art, the present invention has the following beneficial effects:

[0075] (1) The IL-15 insertion fragment enables JY-815iNK cells to have the ability to secrete IL-15 factors by themselves, reducing their dependence on the addition of exogenous factors while enhancing their own proliferation ability and the persistence of their activity in vivo and in vitro.

[0076] (2) The selected exogenous gene fragment insertion site is located within the PD-1 gene exon, which successfully destroys the transcription structure of PD-1 and inhibits the expression of PD-1 protein, thereby enabling JY-815iNK cells to overcome tumor cell tolerance and immune escape caused by the expression of the immune checkpoint PD-1, and enabling JY-815iNK cells to acquire more sustained tumor recognition and killing capabilities.

[0077] (3) The insertion of IL-15 expression gene fragments and the silencing of PD-1 gene improve the overall expansion ability and activity maintenance ability of JY-815 cell-related products, while avoiding the immune escape of tumor cells caused by PD-1 expression, thereby improving the killing function of JY-815iNK cells as a whole.

[0078] (4) The genetic modification of JY-815iNK cells is carried out on an undifferentiated iPS cell line. Gene insertion and knockout occur in undifferentiated iPSCs. The established PSC monoclonal line is permanent and stable. This cell line can be used to produce homogenous iNK cells in unlimited quantities without the need to transfect NK cells with viral vectors, thus avoiding massive cell death caused by viral infection and uncontrollable changes in gene insertion and expression. BRIEF DESCRIPTION OF THE DRAWINGS

[0079] Figure 1 This is the IL-15 expression plasmid map.

[0080] Figure 2 This is a schematic diagram of the insertion site of the IL-15 expression plasmid.

[0081] Figure 3 This is the pluripotency analysis of the JY-815iPSC cell line.

[0082] Figure 4 It is a test of the IL-15 secretion ability of JY-815iNK cells.

[0083] Figure 5 is the expression rate of PD-1 on the membrane surface of JY-815iNK cells.

[0084] Figure 6 It is a test of the IFN-γ secretion ability of JY-815iNK cells.

[0085] Figure 7 This is a test of the killing activity of JY-815iNK cells against K562 cells after long-term in vitro culture.

[0086] Figure 8 This is an in vitro killing activity test of JY-815iNK cells against A549 cells, a non-small cell lung cancer cell line that positively expresses PD-1.

[0087] Fig. 9 This is the animal tumor load detection after a single administration of JY-815iNK cells.

[0088] Fig.10 This is the survival statistics of experimental mice after a single administration of JY-815iNK cells.

[0089] Fig.11 Flow cytometry analysis of IL-15 expression on JY-816iPSCs and JY-817iPSCs.

[0090] Fig.12 It is an in vitro killing activity test of JY-816iNK and JY-817iNK cells. DETAILED DESCRIPTION

[0091] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0092] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0093] Example 1 Screening of single guide RNA (sgRNA) and construction of expression plasmid

[0094] The sgRNA targeting the second exon of PD-1 was designed through the website http: / / crispor.org / crispor.py. Based on the website's prediction of the specificity and effectiveness of sgRNA, the following 8 sgRNAs were preferred. The following single guide RNA (sgRNA) expression plasmids were prepared by connecting the DNA sequence corresponding to the sgRNA downstream of the U6 promoter:

[0095] PD-1-AS12006: SEQ ID NO.1: 5'-GCAGTTGTGACACGGAAG-3';

[0096] PD-1-S17220: SEQ ID NO.2: 5'-GCGTGACTTCCACATGAGCG-3';

[0097] PD-1-AS12029: SEQ ID NO.3: 5'-CATGTGGAAGTCACGCCCGT-3';

[0098] PD-1-AS12055: SEQ ID NO.4: 5'-GGTGCCGCTGTCATTGCGCC-3';

[0099] PD-1-S17245: SEQ ID NO.5: 5'-AGGGCCCGGCGCAATGACAG-3';

[0100] PD-1-AS12012: SEQ ID NO.6: 5'-CGTTGGGCAGTTGGTTGACA-3';

[0101] PD-1-S17260: SEQ ID NO.7: 5'-GACAGCGGCACCTACCTCTG-3';

[0102] PD-1-S17197: SEQ ID NO. 8: 5'-CGTGTCACACAACTGCCCAA-3'.

[0103] Example 2 Construction of donor plasmid

[0104] Genomic DNA was extracted from parental iPSCs (JY-800) using the QIAamp DNA Mini Kit (QIAGEN Cat. 551306) and then used as a template for PCR reactions. To construct the targeted donor plasmid, the upstream and downstream regions of the PD-1 targeting site were amplified from the extracted genomic DNA. These fragments were mixed with the coding sequence of IL-15-T2A-hygromycin phosphotransferase and assembled using the NEBuilder HiFi DNA Assembly Kit (New England BioLabs) to generate the PD-1-IL-15-Hygro targeting plasmid ( Figure 1 ).

[0105] The backbone vector of the donor plasmid is pUC19, and the donor plasmid contains a homologous recombination fragment, and the homologous recombination fragment contains a nucleotide fragment encoding human interleukin 15. The homologous recombination fragment contains an upstream homology arm, an insertion fragment and a downstream homology arm; the insertion fragment includes a promoter element, a nucleotide sequence encoding human interleukin 15 and a poly A element.

[0106] The nucleotide sequence of the inserted fragment is shown in SEQ ID NO.9.

[0107] The sequence of the upstream homology arm is SEQ ID NO.10.

[0108] The sequence of the downstream homology arm is SEQ ID NO.11.

[0109] The sequence of the poly A element is SEQ ID NO.12.

[0110] The nucleotide sequence encoding human interleukin 15 is SEQ ID NO.13.

[0111] Example 3 Transfection of iPSC (JY-800) cell line and preliminary antibiotic screening of constructed cell line

[0112] According to the protocol provided by the kit, the parental iPSC (JY-800) was transfected with the Streptococcus pyogenes Cas9 expression plasmid, sgRNA plasmid and donor plasmid using the Neon transfection system (Thermo Fisher MPK5000). Two days after transfection, the cell line was screened for P1 generation using 50 μg / mL hygromycin, and then P2 and P3 cells were screened using 50 μg / mL hygromycin to obtain P4 cells.

[0113] Example 4 Identification and screening of iPSC (JY-815) cell lines and construction of their cell bank

[0114] The P4 cells obtained in Example 3 were inoculated and cultured in the antibiotic-free iPSC culture medium mTeSR1 (Stemcell; Lot: 85850) for 5-7 days, and then cells in the monoclonal colonies were selected for sequencing and identification. Based on the sequencing comparison results, cells that were successfully transduced with specific gene sequences (such as Figure 2 ) iPS cell line JY-815, and then the selected cell line was cultured, expanded, and frozen for subsequent differentiation.

[0115] Example 5: Pluripotency Analysis of iPSC (JY-815) by Immunofluorescence Staining

[0116] Immunocytochemistry (ICC) analysis of stemness gene indicators such as ALP, TRA-1-60, and NANOG of iPSC (JY-815) strain was performed using alkaline phosphatase substrate kit III (Vector Cat. No. SK-5300), anti-TRA-1-60 antibody, and anti-NANOG antibody, respectively, to identify the pluripotency of iPSC (JY-815). The experimental results are shown in Figure 3 shown.

[0117] The above results showed that the expression ratios of iPSC marker proteins such as ALP, TRA-1-60, and NANOG in the selected JY-815iPS cell line were all over 90%, and the JY-815iPS cell line was successfully constructed.

[0118] Example 6 Induction of differentiation of JY-815 iPS cells

[0119] After inducing differentiation of JY-815iPS cells, JY-815iNK cells are obtained. The preparation method of JY-815iNK cells includes:

[0120] Cultivate JY-815iPS cells; JY-815iPS cells are hematopoietic differentiated, and JY-815iPS cells are placed in a hematopoietic differentiation induction medium for incubation, wherein the hematopoietic differentiation induction medium includes 50ng / mL fibroblast growth factor, 50ng / mL bone morphogenetic protein 4, 50ng / mL stem cell factor, and 20ng / mL vascular endothelial growth factor; JY-815iPS cells are NK differentiated, and the hematopoietic differentiated JY-815iPS cells are placed in a NK differentiation induction medium containing NK differentiation induction medium, wherein the NK differentiation induction medium includes 20% FBS, 10ng / mL interleukin-15, 10ng / mL interleukin-7, 20ng / mL stem cell factor, and 10ng / mL fms-like tyrosine kinase-3 ligand, and fresh culture medium is replaced every 3-4 days, and the JY-815iNK cells are collected after 14-21 days of culture. iNK cells from other sources (JY-800, etc.) in this specification are also prepared according to the specific operation method in this embodiment.

[0121] Example 7 Detection of IL-15 secretion ability of JY-815iNK cells

[0122] JY800-iNK and JY815-iNK cells were collected and washed twice with DPBS. The supernatant of the last centrifugation was collected and recorded as the 0h sample. Then, the cells were resuspended with an appropriate amount of cell culture medium and the cell density was adjusted to 1×10 6 / mL and inoculated, and placed in a 37°C, 5% CO2 incubator for 24h and 72h. The cell supernatant of each group was collected at each time point. After centrifugation to remove the cells, the ELISA detection kit was used to detect the IL-15 secretion of each group of cells. The experimental results are shown in Figure 4 shown.

[0123] The above results indicate that JY815-iNK cells can successfully and continuously secrete IL-15.

[0124] Example 8 Detection and analysis of PD-1 phenotype of JY-815iNK cells

[0125] The expression of PD-1 in JY-815iNK cells after differentiation was detected by flow cytometry:

[0126] The cells were collected and washed, and then the differentiated cells were prepared into a cell suspension. 100 μL of the cell suspension was added to each 15 mL centrifuge tube, followed by 0.1-10 μg / mL of PD-1 antibody. The cells were incubated at room temperature in the dark for 30 minutes, and then the cells were washed three times with PBS and centrifuged at 300 g for 5 minutes. Finally, the cells were resuspended with 0.2 mL of PBS and the expression of PD-1 was detected by flow cytometry. The experimental results are shown in Figure 5 shown.

[0127] The above experimental results show that PD-1 is extremely lowly expressed in JY-815iNK cells, indicating that PD-1 protein expression in JY-815iNK cells has been successfully blocked.

[0128] Example 9 Detection of IFN-γ secretion ability of JY-815iNK cells

[0129] After washing and counting JY815-iNK cells and K562 cells with DPBS, the two cells were inoculated into a 6-well plate at a ratio of 2:1, and set as the co-culture group (JY815 iNK+K562); another group was inoculated with the same iNK cell concentration alone, set as the control group (JY815 iNK). They were then placed together in a 37°C, 5% CO2 incubator, and the supernatant was collected after 4 hours. After centrifugation to remove the cells, the ELISA detection kit was used to detect the IFN-γ secretion of each group of cells. The experimental results are shown in the figure. Figure 6 shown.

[0130] The experimental results showed that JY815 iNK cells exhibited significant cytotoxic activity against K562 cells in vitro.

[0131] Example 10 Detection of the killing ability of JY-815iNK cells against tumor cells (K562)

[0132] 1 × 10 4 K562 cells with fluorescent labels were placed in an incubator containing 5% CO2 and 37°C for later use. Then, 1×10 4 , 2×10 4 JY-815iNK, JY-800iNK and PBMC-NK have been continuously expanded and cultured for 35 days, and 4h and 24h co-culture groups were set up respectively. After adding NK cells from each source, flow cytometry live-death detection analysis was performed on the co-cultured cell wells after 4h and 24h respectively. The experimental results are shown in Figure 7 shown.

[0133] The above results show that after being cultured for more than 35 days, JY-815iNK cells still show stronger killing activity than non-edited cells (JY-800iNK) and equivalent to PB-NK.

[0134] Example 11 Detection of the killing ability of JY-815iNK cells against PD-L1 positive tumor cells (A549)

[0135] PD-L1 is upregulated in a variety of tumor cells (including A549 cell lines). It binds to PD-1 expressed on T / NK cells, inhibits T / NK cell proliferation and activation, and inactivates T / NK cells, ultimately inducing immune escape. In this example, the real-time label-free dynamic cell analysis technology (RTCA, Real Time Cellular Analysis) was used to detect the sustained killing ability of JY-815iNK cells on A549 target cells. The specific operation steps are as follows:

[0136] Take out the RTCA E96 Plate, add 50 μL of the corresponding culture medium to each well, create a new experiment in the RTCA program, complete the relevant experimental settings, put the E-plate in and lock it, the instrument automatically performs baseline measurement, and the baseline measurement is generally completed within one minute; digest the A549 target cells and inoculate them in the E-plate at a rate of 2E4 / well; after inoculation, place it at room temperature for 30 minutes, put the E-plate in the recording tank, and scan it every 15 minutes to record the cell growth; observe the resistance of the target cells, and add JY-815iNK effector cells before and after reaching the plateau phase; add target cells according to the experimental setting effect-target ratio (E:T=1:1; 1:2; 2:1), place the E-plate on the plate, and start recording the killing step after 10 minutes; the rehydration can be paused halfway; after the experiment is completed (recording ≥7 days), analyze and process the data, and the experimental results are as follows Figure 8 shown.

[0137] The results of in vitro killing ability test of PD-L1-positive non-small cell lung cancer cell line A549 using real-time dynamic cell analysis technology showed that the killing efficacy and duration of JY-815iNK cells have comparative advantages over JY-800iNK cells (without gene modification).

[0138] Example 12 Evaluation of the efficacy of JY-815iNK cells in animals after a single administration

[0139] After K562-Luc cells were identified by STR and matched with the ATCC database, the logarithmic growth phase tumor cells were used for inoculation of tumors in vivo. K562-Luc cells were resuspended in PBS at a concentration of 2.5×10 7 / mL, inoculated into the experimental animals through tail vein injection, 200μL / animal; after inoculation of K562-Luc cells, grouping and drug administration began on the third day (D3) according to BLI values ​​and body weight, and 5 experimental groups were set up, including tumor model control group, JY-800iNK cell administration group, JY-815iNK cell administration group, blank control group and JY-815iNK cell dosage increase administration group; then, bioluminescence live imaging was performed using a small animal live imaging instrument every 3-4 days, and the survival data of animals in each experimental group were continuously recorded ( Fig. 9 , Fig.10 ).

[0140] The experimental results showed that after administration into mice, JY-815iNK cells were superior to JY-800iNK cells in inhibiting the growth of K562 tumor cells and prolonging the survival of tumor-bearing mice.

[0141] Example 13

[0142] This embodiment provides a series of functionally enhanced iPSC-derived NK cells, wherein the functionally enhanced iPSC-derived NK cells are differentiated and induced by recombinant induced pluripotent stem cells. The method for preparing the recombinant induced pluripotent stem cells comprises:

[0143] (1) Using initial induced pluripotent stem cells as starting cells, the expression of PD-1 was blocked and membrane-bound human interleukin 15 was overexpressed to obtain recombinant induced pluripotent stem cells JY-816.

[0144] (2) Using initial induced pluripotent stem cells as starting cells, blocking the expression of PD-1 and overexpressing a protein fused with part or all of the domains of human interleukin 15 and interleukin 15 receptor subunit α to obtain recombinant induced pluripotent stem cells JY-817.

[0145] The construction process of the recombinant induced pluripotent stem cells refers to the construction process of the "iPS cell line JY-815", wherein the insert fragment in the donor plasmid used to prepare the recombinant induced pluripotent stem cell JY-816 is shown in SEQ ID NO.14; the insert fragment in the donor plasmid used to prepare the recombinant induced pluripotent stem cell JY-817 is shown in SEQ ID NO.15.

[0146] The above two donor plasmids were used to perform gene editing on iPSCs through Crispr / Cas9, and positive clones were obtained after sorting, namely JY-816 and JY-817 iPSCs. IL-15 expression in JY-816 and JY-817 iPSCs was detected by flow cytometry using IL-15 antibodies, as shown in Figure 2. Fig.11 As shown, JY-816( Fig.11Middle A) and JY-817( Fig.11 In B), both expressed IL-15. Recombinant induced pluripotent stem cells JY-816 and JY-817 were induced to differentiate, respectively, and the differentiation induction steps were referred to Example 6. Functionally enhanced iPSC-derived NK cells JY-816 and JY-817 were obtained.

[0147] The function-enhanced iPSC-derived NK cells JY-816 and JY-817 were cultured respectively, and the killing ability of the above cells on the tumor cell K562 was detected. The experimental steps are as follows:

[0148] 1 × 10 4 K562 cells with fluorescent labels were placed in an incubator containing 5% CO2 and 37°C for later use. Then, 1×10 4 , 2×10 4 JY-816iNK, JY-817iNK and PB-NK have been continuously expanded and cultured for 35 days, and 4h and 24h co-culture groups were set up respectively. After adding NK cells from each source, flow cytometry live-death detection analysis was performed on the co-cultured cell wells after 4h and 24h respectively. The experimental results are shown in Fig.12 shown.

[0149] from Fig.12 It can be seen that functionally enhanced iPSC-derived NK cells constructed based on membrane-bound human interleukin 15 and fusion protein (a protein expressed by fusion of part or all of the domains of human interleukin 15 and interleukin 15 receptor subunit α) can also exert a good tumor-killing effect.

[0150] In summary, the present invention provides a method for constructing a functionally enhanced iPSC-derived NK cell and an iPS cell line capable of producing such specific NK cells. The iNK cells in the present invention can autosecrete IL-15, which enables them to have a long-lasting activity retention ability and tumor killing ability both in vitro and in vivo. At the same time, the iNK cells overcome the tumor cell tolerance and immune escape caused by the expression of the immune checkpoint PD-1 because of the blocked expression of the PD-1 protein, showing further functional enhancement.

[0151] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A recombinant induced pluripotent stem cell, characterized in that: The recombinant induced pluripotent stem cells are prepared by a method comprising the following steps: using initial induced pluripotent stem cells as starting cells, blocking / inhibiting the expression of PD-1 and overexpressing human interleukin 15; The human interleukin 15 includes any one of the following: (1) Human interleukin 15; (2) membrane-bound human interleukin-15; (3) A protein expressed by fusion of part or all of the structural domains of human interleukin 15 and interleukin 15 receptor subunit α.

2. The recombinant induced pluripotent stem cell according to claim 1, characterized in that The method for blocking / inhibiting the expression of PD-1 and overexpressing human interleukin 15 comprises: The CRISPR / Cas9 gene editing system was used to insert a homologous recombination fragment containing a nucleotide fragment encoding human interleukin 15 into the PD-1 gene, thereby blocking / inhibiting the expression of PD-1 while overexpressing human interleukin 15.

3. The recombinant induced pluripotent stem cell according to claim 2, characterized in that The CRISPR / Cas9 gene editing system includes sgRNA, Cas9 plasmid and donor plasmid; Preferably, the donor plasmid contains a homologous recombination fragment, and the homologous recombination fragment contains a nucleotide fragment encoding human interleukin 15; Preferably, the homologous recombination fragment comprises an upstream homology arm, an insertion fragment and a downstream homology arm; Preferably, the inserted fragment comprises a promoter element, a nucleotide sequence encoding human interleukin 15 and a poly A element; Preferably, the poly A element is selected from SV40, and a transcription terminator is further included after the poly A element, and the transcription terminator is selected from any one of bGH, hGH or rbGlob; Preferably, the promoter is selected from any one of PGK, CAG, CMV, EF1a or UBC; Preferably, the amino acid sequence of human interleukin 15 includes that shown in SEQ ID NO.16; the nucleotide sequence encoding human interleukin 15 includes that shown in SEQ ID NO.13; Preferably, the amino acid sequence of the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.17; the nucleotide sequence encoding the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.18; Preferably, the protein expressed by fusion of part or all of the structural domains of human interleukin 15 and interleukin 15 receptor subunit α is a protein expressed by fusion of the extracellular domain and transmembrane domain of human interleukin 15 and interleukin 15 receptor subunit α, and its amino acid sequence includes that shown in SEQ ID NO.19; the nucleotide sequence encoding the fusion expressed protein includes that shown in SEQ ID NO.20; Preferably, the nucleotide sequence of the inserted fragment is shown as SEQ ID NO.

9.

4. The recombinant induced pluripotent stem cell according to claim 2 or 3, characterized in that The sgRNA targets exon 1 or 2 of the PD-1 gene of induced pluripotent stem cells; Preferably, the DNA sequence corresponding to the sgRNA includes any one of SEQ ID NO.1-8; PD-1-AS12006: SEQ ID NO.1: 5'-GCAGTTGTGACACGGAAG-3'; PD-1-S17220: SEQ ID NO.2: 5'-GCGTGACTTCCACATGAGCG-3'; PD-1-AS12029: SEQ ID NO.3: 5'-CATGTGGAAGTCACGCCCGT-3'; PD-1-AS12055: SEQ ID NO.4: 5'-GGTGCCGCTGTCATTGCGCC-3'; PD-1-S17245: SEQ ID NO.5: 5'-AGGGCCCGGCGCAATGACAG-3'; PD-1-AS12012: SEQ ID NO.6: 5'-CGTTGGGCAGTTGGTTGACA-3'; PD-1-S17260: SEQ ID NO.7: 5'-GACAGCGGCACCTACCTCTG-3'; PD-1-S17197: SEQ ID NO. 8: 5'-CGTGTCACACAACTGCCCAA-3'.

5. A recombinant plasmid expressing human interleukin 15, characterized in that: The recombinant plasmid contains a homologous recombination fragment, and the homologous recombination fragment contains a nucleotide fragment encoding human interleukin 15; Preferably, the human interleukin 15 includes any one of the following: (1) Human interleukin 15; (2) membrane-bound human interleukin-15; (3) A protein expressed by fusion of part or all of the domains of human interleukin 15 and interleukin 15 receptor subunit α; Preferably, the homologous recombination fragment comprises an upstream homology arm, an insertion fragment and a downstream homology arm; Preferably, the inserted fragment comprises a promoter element, a nucleotide sequence encoding human interleukin 15 and a poly A element; Preferably, the poly A element is selected from SV40; the poly A element further comprises a transcription terminator, and the transcription terminator is selected from any one of bGH, hGH or rbGlob; Preferably, the promoter is selected from any one of PGK, CAG, CMV, EF1a or UBC; Preferably, the amino acid sequence of human interleukin 15 includes that shown in SEQ ID NO.16; the nucleotide sequence encoding human interleukin 15 includes that shown in SEQ ID NO.13; Preferably, the amino acid sequence of the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.17; the nucleotide sequence encoding the membrane-bound human interleukin 15 includes that shown in SEQ ID NO.18; Preferably, the protein expressed by fusion of part or all of the structural domains of human interleukin 15 and interleukin 15 receptor subunit α is a protein expressed by fusion of the extracellular domain and transmembrane domain of human interleukin 15 and interleukin 15 receptor subunit α, and its amino acid sequence includes that shown in SEQ ID NO.19; the nucleotide sequence encoding the fusion expressed protein includes that shown in SEQ ID NO.20; Preferably, the nucleotide sequence of the inserted fragment is shown as SEQ ID NO.9; Preferably, the backbone vector of the recombinant plasmid is pUC19.

6. The use of the recombinant plasmid expressing human interleukin 15 according to claim 5, characterized in that: The applications include: (a) as a donor plasmid for in vitro genetic modification of any stem cell including iPSC, ESC, or any immune cell including NK cell, T cell, γδT cell, NKT or macrophage; (b) as a donor plasmid for in vivo gene editing; (c) As a donor plasmid for gene therapy.

7. Use of the recombinant induced pluripotent stem cell according to any one of claims 1 to 4 in the preparation of any one of function-enhanced iPSC-derived NK cells, T cells, γδT cells, NKT cells, macrophages or MSC cells.

8. A functionally enhanced iPSC-derived NK cell, characterized in that: The NK cells are obtained by culturing the recombinant induced pluripotent stem cells according to any one of claims 1 to 4 through hematopoietic differentiation; Preferably, the step of hematopoietic differentiation culture comprises: (1) Hematopoietic differentiation: placing the recombinant induced pluripotent stem cell according to any one of claims 1 to 4 in a hematopoietic differentiation induction medium for incubation; (2) NK differentiation: placing the recombinant induced pluripotent stem cells after hematopoietic differentiation in a NK differentiation induction medium for incubation; obtaining the functionally enhanced iPSC-derived NK cells; Preferably, the hematopoietic differentiation induction medium comprises, by concentration: 20-60 ng / mL fibroblast growth factor, 20-60 ng / mL bone morphogenetic protein 4, 5-100 ng / mL stem cell factor, and 10-30 ng / mL vascular endothelial growth factor; Preferably, the NK differentiation induction medium comprises, by concentration: 5-25% FBS, 5-50 ng / mL interleukin-15, 5-50 ng / mL interleukin-7, 5-100 ng / mL stem cell factor, and 5-100 ng / mL fms-like tyrosine kinase-3 ligand.

9. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the function-enhanced iPSC-derived NK cells according to claim 8; Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

10. Use of the recombinant induced pluripotent stem cells according to any one of claims 1 to 4, the functionally enhanced iPSC-derived NK cells according to claim 8, and / or the pharmaceutical composition according to claim 9 in the preparation of tumor therapeutic drugs.

Citation Information

Cited By

  • Universal human induced pluripotent stem cell, mDAP / mDA cell and application

    CN121780445A

  • CXCR4 high-expression type iPSC-NK cell capable of enhancing bone marrow and tumor tissue homing ability, and preparation method and application of CXCR4 high-expression type iPSC-NK cell

    CN122104589A